Pharmaceutical News

RSS

Biologists determine three-dimensional structure of molecule involved in HIV, cancer

In a technical tour de force, structural biologists funded by the National Institutes of Health have determined the three-dimensional structure of a molecule involved in HIV infection and in many forms of cancer. The high-resolution structure sheds light on how the molecule functions and could point to ways to control its activity, potentially locking out HIV and stalling cancer's spread.

8 Oct 2010

Suneva Medical publishes Artefill data for treatment of atrophic acne scars

Suneva Medical, a privately-held aesthetic medical device company, today announced the publication of an open-label, single center, pilot study on Artefill for the treatment of atrophic acne scars conducted by James M. Spencer, M.D. M.S. and sponsored by Suneva Medical.

8 Oct 2010

CMA to apply intervener status in Insite case

The Canadian Medical Association (CMA) Board of Directors has decided that the CMA will apply for intervener status before the Supreme Court of Canada in its pending appeal of a case involving Insite, the supervised injection facility in Vancouver, British Columbia.

8 Oct 2010

MRSA pathogen influences U.S. physician drug selection for treating skin structure infections

Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed U.S. physicians with regard to their treatment of skin and skin structure infections.

8 Oct 2010

Spanish mothers more concerned about the safety of childhood vaccines

Researchers from the University of Alicante (UA) taking part in the European VACSATC project have studied mothers' and fathers' opinions on vaccinating their children in five countries. The results of the survey show that Spanish mothers are more resistant than those in other countries to the idea of paying for vaccines, while 20.9% expressed some concern about the safety of vaccines.

8 Oct 2010

CDC issues new universal influenza vaccination recommendation for all Americans

With the influenza vaccine already available and more supply anticipated than ever before, the National Foundation for Infectious Diseases convened ten of the country's leading medical and public health groups to call on all Americans to get vaccinated this season.

8 Oct 2010

IV ibuprofen effective in reducing fever in hospitalized patients

Cumberland Pharmaceuticals Inc. today announced the publication of data affirming the safety and efficacy of Caldolor (ibuprofen) Injection in treating fever in critically ill and non-critically ill adults. Published in the peer-reviewed journal Critical Care, the study showed that IV ibuprofen was significantly more effective at reducing fever in hospitalized patients than placebo.

8 Oct 2010

Firm sees drugs sales rising 5 to 7 percent next year, other drug industry news

The Associated Press reports that global prescription drug sales should rise 5 percent to 7 percent next year reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm IMS Health.

8 Oct 2010

Endo grants Watson royalty-free license to U.S. patents

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Endo Pharmaceuticals, Inc. on outstanding patent litigation related to Endo's Opana ER (Oxymorphone ER) product.

8 Oct 2010

Emergent BioSolutions and TLV form new joint venture to develop flu vaccines

Emergent BioSolutions Inc., a U.S.-based developer and manufacturer of vaccines and antibody therapies, today launched its Singapore operations.

8 Oct 2010

U.N. Secretary-General urges funding for GAVI during replenishment meeting

U.N. Secretary-General Ban Ki-moon has urged more funding for the GAVI Alliance to help achieve its childhood vaccine targets and the related Millennium Development Goals (MDGs), TopNews reports.

8 Oct 2010

NIAID announces three new contracts to fund research on dengue, anthrax vaccines

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today announced three new contracts to fund research on vaccines to protect against emerging infectious diseases and biological threats that could be used in a terror attack. Each project focuses on simple and efficient vaccine delivery approaches that could be deployed quickly. The total funding for the three contracts could reach $68 million, depending on the successful completion of defined project milestones.

8 Oct 2010

Novel peptide NX002 demonstrates efficacy in animal model of oral mucositis: Study

NephRx Corporation today announced that a new study has shown that its novel peptide NX002 demonstrated significant efficacy when tested in an animal model of oral mucositis. Mucositis is a debilitating and often dose-limiting side effect of many forms of cancer therapy that affects more than 400,000 patients who receive chemotherapy or radiation treatment in the U.S. each year. Current treatment options are very limited.

8 Oct 2010

Inviragen, PharmaJet awarded NIAID contract to develop needle-free, easy to administer dengue vaccine

Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the development of a needle-free, easy to administer dengue vaccine. The award will fund preclinical studies, regulatory filings, manufacturing and clinical testing of Inviragen's tetravalent dengue vaccine, DENVax delivered with PharmaJet's convenient needle-free injection device.

8 Oct 2010

NIAID awards $6.25M to Profectus to optimize portfolio of genetic adjuvants

Profectus BioSciences, Inc., a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases, today announced that it has received $6.25M in National Institute of Allergy and Infectious Disease (NIAID) grants and contracts.

8 Oct 2010

FDA files complaint for permanent injunction against Brooklyn Juice Company

At the request of the U.S. Food and Drug Administration, the U.S. Department of Justice today filed a complaint for permanent injunction against a Brooklyn juice company to prevent it from processing and distributing juice products.

8 Oct 2010

USPTO issues Patent Notice of Allowance for CIP-TRAMADOL ER drug

Cipher Pharmaceuticals Inc. today announced that the U.S. Patent and Trademark Office has issued a Patent Notice of Allowance for CIP-TRAMADOL ER, the Company's extended-release tramadol product for the treatment of moderate to moderately severe chronic pain in adults.

8 Oct 2010

CQ Healthbeat examines HIV prevention research funding

The global economy has affected HIV/AIDS prevention research, so "scientists and those who fund them are struggling to set priorities among several competing research methods that could slow the spread of the disease, which causes about 2.7 million new infections worldwide a year," CQ HealthBeat reports.

8 Oct 2010

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

Onyx Pharmaceuticals, Inc. today announced that it will delay its New Drug Application (NDA) filing for carfilzomib based on a recent meeting with the Chemistry, Manufacturing and Controls (CMC) review division of the U.S. Food and Drug Administration (FDA).

7 Oct 2010

Vical to manufacture pDNA vaccines against HIV

Vical Incorporated today announced that the company has agreed to manufacture plasmid DNA (pDNA) vaccines against HIV under a $2.4 million contract with the IPPOX Foundation, a collaborating institution for the Poxvirus Vaccine Regimen Design (PVRD) led by the Centre Hospitalier Universitaire Vaudois (CHUV) under the auspices of the Collaboration for AIDS Vaccine Discovery (CAVD).

7 Oct 2010